Literature DB >> 12241116

Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor.

C Morales1, M Zurita, J Vaquero.   

Abstract

Taxoids are effective agents against a wide variety of tumors, but their effectiveness on neuroectodermal tumors is not well-known. For this reason we have carried out an experimental study on the effect of intratumoral administration of docetaxel (DC) and paclitaxel (PC) on tumor growth, using a murine model of malignant neuroectodermal tumor. The results showed a delay in tumor growth in animals treated with PC compared with controls (dose of 5 mg/kg, three times per week every other day, forming a cycle; three cycles were completed with a break of a week between each cycle). The total dose administered to each animal was 45 mg/kg. When DC was administered, the results showed distinct tumor growth inhibition and tumor regression in 80% of animals (intratumoral administration at a dose of 5 mg/kg, three times per week every other day forming a cycle; three cycles were completed with a break of a week between each cycle). The total dose administered to each animal was 20 mg/kg. These results suggest the utility of taxoids, mainly DC, by intralesional administration, on malignant tumors of the nervous system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12241116     DOI: 10.1023/a:1019979813640

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

2.  Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.

Authors:  M C Chamberlain; P A Kormanik
Journal:  J Clin Oncol       Date:  1997-12       Impact factor: 44.544

3.  Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.

Authors:  E Boven; E Venema-Gaberscek; C A Erkelens; M C Bissery; H M Pinedo
Journal:  Ann Oncol       Date:  1993-04       Impact factor: 32.976

4.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme.

Authors:  P J Moos; D T Muskardin; F A Fitzpatrick
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

Review 6.  Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.

Authors:  B Fulton; C M Spencer
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Cytotoxicity of taxol in vitro against human and rat malignant brain tumors.

Authors:  M A Cahan; K A Walter; O M Colvin; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.

Authors:  K A Walter; M A Cahan; A Gur; B Tyler; J Hilton; O M Colvin; P C Burger; A Domb; H Brem
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

9.  Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).

Authors:  D J Dykes; M C Bissery; S D Harrison; W R Waud
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 10.  Preclinical evaluation of docetaxel (Taxotere).

Authors:  F Lavelle; M C Bissery; C Combeau; J F Riou; P Vrignaud; S André
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929

View more
  1 in total

1.  Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma.

Authors:  Elisabeth Miot-Noirault; Jean Legault; Florent Cachin; Emmanuelle Mounetou; Françoise Degoul; René C Gaudreault; Nicole Moins; Jean Claude Madelmont
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.